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Abstract
Estrogens rapidly decline at the onset of menopause, putting women at higher risk of
osteoporosis, obesity, and neurodegenerative diseases, including Alzheimer’s disease (AD).
Estradiol hormone therapies (HT) have been suggested to limit these negative effects on women,
with controversial findings as to their effectiveness. A study at OHSU recently found
differentially expressed genes (DEGs) using RNAseq between ovariectomized/hysterectomized
(OvH) old (range = 19.4–23.2 years) female rhesus macaques on HT and those on a placebo on
chronic western style diet (WSD). The DEGs identified in the amyloid processing pathway of the
amygdala were selected for validation using RT-qPCR because β-amyloid peptide (Aβ), made in
the amyloid processing pathway, has a strong correlation with AD risk. The selected genes were:
AKT3, APP, CAPN1, CAPNS1, CSNK2A1, CSNK2A2, MAPK1, MAPK14, MAPT, MARK1,
NCSTN, PRKAR1A, PRKAR2A, PRKAR2B, and PRKCE. All the genes tested were found to be
significantly downregulated (p <0.05) in the OvH-HT females. These genes were also tested in
another set of old and young female rhesus macaques on a standard diet (SD) and were not
differentially expressed using qPCR. Since the RNAseq analysis used a cutoff of 2.3logCPM to
select genes, the qPCR tests confirming the DEGs at this level tells us 2.3logCPM is a valid
cutoff to use in future RNAseq analysis. The genes in the amyloid processing pathway being
significantly downregulated with HT suggests beneficial effects of the HT with WSD because
this pathway regulates Aβ and accumulation of Aβ plaques in the brain are a hallmark of AD.
Introduction
The importance of estrogens during menopause
Each year in the United States, approximately 1.3 million women become menopausal.
Menopause is physiological status characterized by the non-pathological cessation of menses for
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at least 12 months as a result of estrogen deficiency, which occurs naturally in human females
during mid to late adulthood [1]. Estradiol is an estrogen that is a key hormone involved in many
biological functions through complex processes like those of thermoregulation, circadian
pathways, and neuroendocrine pathways [2-5]. Upon the loss of estradiol in menopause, many of
the processes that estrogen once regulated begin altering, leading to adverse physiological
effects. For instance, menopause has been liked to osteoporosis, which affects more than 250,000
menopausal and postmenopausal women, higher rates of coronary heart disease [1], and
psychiatric disorders like sleep disruptions, memory loss, and mood disorders [6]. Given the
critical and diverse physiological roles of estradiol, maintaining estrogen levels close to the premenopause levels has been the gold standard for preventing menopause-related health issues.
Menopause and hormonal replacement therapy
Women are almost two times more at risk of developing Alzheimer’s Disease (AD) as
men, which is not fully explained by lifespan differences between sexes [7-8]. This risk is even
higher in postmenopausal women, which lead to establishing a link between menopause and
cognitive decline [5, 9]. This cognitive decline can include psychological impacts like
depression, anxiety, and neurodegenerative diseases [10].
As a preventative measure to offset these potential negative effects of menopause,
estradiol hormone therapies (HT) have been traditionally prescribed to women in menopause to
reduce risk of AD and mild cognitive impairment through the menopausal transition [11].
Results from such HT studies are controversial in their findings. Studies from the Women’s
Health Initiative estimated overall health risks to be greater than the benefits, with increases in
risk of stroke, breast cancer and cardiovascular disease [7-8, 10, 12]. Meanwhile, other studies
have found benefits of HT with improved psychological well-being and self-esteem, decreased
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adipose tissue, fasting serum glucose and insulin levels, and decreased bone density loss [13-15].
It has been suggested that the positive effects may be due to administered HT during a particular
“window of opportunity,” where HT can be given to peri and pre- menopausal women to prevent
menopausal-related cognitive decline [10-12, 16]. In animal models and human studies, research
has identified the beneficial effects of HT if the therapy is administered at the onset of
menopause during this “window of opportunity,” [17-22].
Menopause and Obesity
During estrogen deficiency, metabolic dysfunction is promoted and predisposes women
to obesity, metabolic syndrome, and type II diabetes [23], as well as increased bone density loss
and cardiovascular risk [11, 24]. Obesity is a leading cause of morbidity and mortality in the U.S.
[25] with 42.4% of the population considered to be obese in 2018 according to the CDC [26].
Factors such as ethnicity, genetic predisposition and rapid fall of estrogen levels can all
contribute to increased body weight [27], along with diet. Western style diet (WSD) is
considered to be a major contributor to the obesity epidemic worldwide with high fat and
sodium, high calories, and excess sugar [28]. Moreover, obesity has been identified as a major
risk factor for cognitive decline and AD development [29]. Given that many women going
through menopause experience significant weight gain [30], it remains largely uninvestigated
how obesity and estrogen in HT interact [25].
Macaque Model to study menopause and HT
Rhesus macaques present suitable animal model to study menopause because they have the
most robustly studied reproductive senescence of all nonhuman primates and females undergo
similar endocrine changes as human females in late adulthood, resembling a menopausal
transition [31]. These animals also exhibit similar neuroendocrine changes in the brain as
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humans with age [31]. Furthermore, in aged female rhesus macaque research models, studies
showed possible benefits of HT administered to ovariectomized/hysterectomized (OvH) females
[17-19]. The benefits observed included reduced anxiety-like behaviors and reduced
sedentariness as seen in other females on obesogenic diet [17-22, 32]. Positive memory and
cognitive effects have also been seen in aged female OvH rhesus macaques on obesogenic diets,
particularly if HT starts immediately after estradiol is removed [33].
Recent Findings
Because women are at higher risk for neurocognitive diseases during and after menopause and
this prevalence is increased in obese and overweight women, the molecular mechanisms behind
these changes were looked at further in a recent study at Oregon Health and Science University
(OHSU). At OHSU an in-depth transcriptome analysis was performed on brain tissues collected
from old OvH female rhesus macaques that received chronic HT while on an obesogenic diet
[34]. Aged female rhesus macaques (range = 19.4-23.2 years) were OvH and kept on a high fat,
high sugar Western-style diet (WSD) for 30 months. Half of the females received HT
immediately following OvH and half were placebo controls. From RNAseq data, the study
identified a total of 6,170 differentially expressed genes (DEGs) among the control and HTtreated groups from these tissues: occipital cortex (OC), prefrontal cortex (PFC), hippocampus
(HIP), and amygdala (AMG). These brain regions were chosen because they contribute to
cognitive function, learning, and memory [35-40]. Of the 6,170 DEGs identified, the AMG had
the most DEGs (4,993). Pathway enrichment analysis found neuroinflammation downregulation
in the AMG. The signaling pathways for synaptogenesis, circadian rhythm, mitochondrial
dysfunction, mTOR, glutamate, serotonin, GABA, dopamine, noradrenaline/adrenaline,
glucocorticoid receptor signaling, neuronal NOS and amyloid processing were exclusively
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enriched in AMG. Taken together, these pathways’ gene expression being altered expand the
link between cognitive decline and obesity, and that the AMG is impacted by AD progression
[34]. The signaling pathways for amyloid processing in the AMG, along with other findings from
the study indicate a protective role for estradiol HT to prevent some of the negative health effects
of individuals on obesogenic diets going through menopause.
Amyloid Processing as the focus of This Study
This study functions as a follow-up on the Cervera-Juanes et al. paper [34] and continues
analysis of the amyloid processing signaling pathway for genes that might be involved in the
development of amyloid plaques in OvH macaques. This pathway was of particular interest
because amyloid plaques are a hallmark of AD [41]. Amyloid plaques are made up of β-amyloid
peptide (Aβ) extracellular deposits in the brain [42]. AD can be genetically inherited in families
when mutations in some of the genes for amyloid processing are inherited, such as the APP gene
(β-amyloid precursor protein), PS1 or PS2 (presinilin-1 or -2) [42]. Alterations in gene
expression linked to a chronic obesogenic diet may be linked to the increased risk for AD in
obese and menopausal women.
Using RT-qPCR, this study seeks to validate the RNAseq findings from the CerveraJuanes et al. paper [34] using the same RNA from AMG tissue samples. In the RNAseq study,
the cutoff for including genes in the study was 0.2 CPM for AMG, which is approximately 10
reads per minimum library size [43]. A fold change greater than or equal to 1.25 and a p-value
less than or equal to 0.05 was used to select DEGs. Given the relaxed cutoff that was used, this
study seeks to validate the RNAseq findings within the amyloid pathway using reverse
transcription-quantitative polymerase chain reaction (RT-qPCR). Our results provide valuable
evidence to confirm the previous RNAseq findings and support a protective relationship of HT
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against alterations in the amyloid pathway in ovariectomized females chronically exposed to an
obesogenic diet.
Methods
These studies and their respective subjects were approved by the Oregon National
Primate Research Center (ONPRC) Institutional Animal Care and Use Committee.
Experiment 1 Subjects
The subjects in this study are the same as those previously described [34] and are
comprised of 14 old (range = 19.4–23.2 years) female rhesus macaques (Macaca mulatta). They
were maintained on a WSD (TAD Primate Diet; LabDiet, Inc) for the duration of the study
(figure 1). WSD was composed of calories with 36% fat, 44% carbohydrates (includes 18.5%
sugars), and 18% protein [34]. At the 6-week mark into the study, animals were OvH and half
began HT (figure 1).

Figure 1 Study design for animals in experiment 1, with WSD introduced at month 0 of study. OvH took place at 6
weeks into the study, and HT began for half (n=7) of the study subjects. Necropsies were performed at the end of the
30-month study period.

Experiment 2 Subjects
The subjects of this study are comprised of 7 young (range = 9.8-13.9 years) and 7 old
(range = 21.8 – 26.1 years) female rhesus macaques (Macaca mulatta). They were housed under
the same conditions as previously described [34] with the same daily mealtimes and
supplemental foods provided as the animals in experiment 1. For the duration of the study, they
were maintained on a standard diet (Monkey Diet, LabDiet, Inc., St Louis, MO, USA) composed
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of calories with 13% fat, 69% complex carbohydrates (includes 6% sugars), and 18% protein.
These subjects were not OvH nor received HT.
Euthanasia
The same process was used after the 30-month duration of the studies for each
experiment as previously described [34]. The euthanasia was performed by trained ONPRC
Division of Comparative Medicine Veterinarians following guidelines set forth by the Panel on
Euthanasia of the American Veterinary Medical Association. The same methods to isolate AMG
tissue were used across all animals as described previously [34].
RNA isolation
Experiment 1 samples were the same AMG RNA from the Cervera-Juanes et al. paper
[34]. RNA was isolated from experiment 1 and 2 AMG tissue samples per the manufacturer’s
recommendations using the All-Prep DNA/RNA/miRNA Universal Kit (Qiagen Sciences Inc.
Germantown, MD). RNA was quantified using Epoch Microplate Spectrophotometer (BioTek,
Winooski, VT, USA).
Reverse Transcription
RNA from experiment 1 and 2 AMG tissue was reverse transcribed to complimentary
DNA (cDNA) using 25ng of AMG RNA. RNA (25ng) from each sample was pooled to create a
stock that was then serially diluted to create an 8-point standard curve to test the efficiency of the
primers used in this study. The SuperScript IV First-Strand Synthesis (Invitrogen, Waltham, MA,
USA) was used to create cDNA. Samples were stored at - 20°C until use for qPCR testing within
the manufacturers recommended storage time.
Another set of 25ng of AMG RNA was reverse transcribed using the Fluidigm Reverse
Transcription Master Mix (Fluidigm, San Francisco, CA, USA) according to the manufacturer’s
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instructions for all experiment 1 and 2 samples individually. RNA (25ng) from each sample in
experiment 1 and 2 was pooled to create a stock that was then serially diluted to create an 8-point
standard curve. The cDNA was then pre-amplified with 10 cycles using Fluidigm Pre-amp
Master Mix and excess primers were removed via Exonuclease I digestion, per manufacturer’s
instructions. Pre-amplified samples were then diluted by 5x with 18µL TEKnova DNA
Suspension Buffer (TEKnova, Hollister, CA, USA) and stored at - 20°C until use for qPCR
testing within the manufacturers recommended storage time.
Primer Design
Primers for Quantitative real-time PCR analysis (RT-qPCR) were designed via the NCBI
Primer-BLAST tool [44]. Using NCBI Gene tool [45], the mRNA sequences of a subset of
DEGs from the RNAseq analysis [34] that were selected for validation (table 1) were searched
using the most up to date version of the Macaca mulatta genome (Taxid ID: 9544, Mmul10).
NCBI reference sequences for mRNA transcripts were selected from each gene and used as the
PCR template in Primer-BLAST. Parameter search values that differed from the default were as
follows: “PCR product size” was Min=90 and Max=200, “Organism” was Macaca mulatta
(Taxid ID:9544), and “Allow splice variants” was selected. Genes which had no primer pair
results in the last 25% of the coding region for the selected mRNA transcript were re-searched in
Primer-BLAST. The new search parameters also included range “Forward primer: From” and
“Reverse primer: To” values which spanned the last 25% of the coding region for said gene
transcript.
In order to identify the most stable housekeeping genes for the amygdala, we selected and
tested the stability of several commonly used housekeeping genes [46-50]: ACTG1, EIF4A2,
PGK1, TOP1, CYC1, GAPDH, RPL13, and UBE2D2. These genes were run in a qPCR to check
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for primer efficiencies and stability in the amygdala tissue. These primers sequences are listed in
table 1.
The DEGs selected for validation using microfluidic RT-qPCR (see below) were from the
Cervera-Juanes et al. paper amyloid processing pathway (APP, PRKAR2A, CAPN1, PRKAR2B,
CSNK2A1, CAPNS1, CSNK2A2, MAPK14, PRKCE, MAPT, MARK1, AKT3, PRKAR1A, MAPK,
NCSTN). These gene primers are listed in table 2.
Quantitative real-time PCR analysis – QuantStudio
qPCR to test housekeeping genes stability and efficiency was performed using
QuantStudio 12K Flex system (Applied Biosystems, Waltham, MA, USA). Samples and assays
were prepared according to manufacturer’s directions using PowerUp SYBR Green Master Mix
(Applied Biosystems). Sample/Assay mixes were prepared with 6µl SYBR, 3µl water, 1µl
forward and reverse primer at 10µM, and 1µl cDNA (concentration dependent on serial dilution
sample used) per well in a 384-well plate. Sample/Assay mixes were then pipetted into a
standard 384-well plate for thermocycling. Thermocycling qPCR conditions were as follows:
95°C for 60s, 35 cycles of 95°C for 5s and 58°C for 20s. Data was processed through automatic
threshold for each assay, with derivative baseline correction using QuantStudio 12K Flex system
(Applied Biosystems). The primer sequences are listed in Table 2.
Microfluidic quantitative real-time PCR analysis - Fluidigm
Following manufacturer’s instructions, the sample and assay pre-mixes were prepared as
previously described, then loaded into a 48.48 GE Dynamic Array IFC (Fluidigm) in duplicate
assays using the Nanoflex IFC controller (Fluidigm). Thermocycling qPCR conditions were
95°C for 60s, 35 cycles of 95°C for 5s and 58°C for 20s. Data was processed through automatic
threshold for each assay. Then, derivative baseline correction was made using BioMark
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RealTime PCR Analysis Software 3.1.2 (Fluidigm) with quality threshold set at 0.65. The primer
sequences are listed in table 3.
Table 1 Genes selected for validation using RT-qPCR. Data taken from Cervera-Juanes et al. paper RNAseq
analysis of the AMG amyloid processing pathway DEGs [34].

Gene name
AKT3
APP
CAPN1
CAPNS1
CSNK2A1
CSNK2A2
MAPK1
MAPK14
MAPT
MARK1
NCSTN
PRKAR1A
PRKAR2A
PRKAR2B
PRKCE

log FC
-0.60
-0.47
-0.72
-0.55
-0.52
-0.47
-0.84
-0.83
-0.56
-0.37
-0.59
-0.52
-0.89
-0.68
-0.49

FC
1.51
1.39
1.65
1.46
1.43
1.38
1.79
1.78
1.48
1.29
1.50
1.44
1.86
1.60
1.40

p-value
1.80E-02
1.60E-02
<0.0001
1.00E-03
2.00E-03
1.00E-02
<0.0001
4.00E-03
1.70E-02
4.30E-02
<0.0001
3.00E-03
<0.0001
5.00E-03
4.00E-03

fdr
9.70E-02
9.00E-02
2.00E-03
1.40E-02
2.70E-02
6.90E-02
2.00E-03
4.20E-02
9.50E-02
1.61E-01
1.00E-02
3.60E-02
1.00E-03
4.50E-02
3.0E-02

Table 2 Forward and reverse primers for the QuantStudio RT-qPCR housekeeping genes test for efficiency and
reliability.

Amplicon Annealing
Gene name Forward primer (5' to 3')
Reverse primer (5' to 3')
Size
Temp (°C)
CYC1
GGCATGGTGGTGTAGGACTAC
TAGAGACCTTCCCGCAGTGA
86
58
UBE2D2
TGCCTGAGATTGCTCGGATCT
TCGCATACTTCTGAGTCCATTCC
81
58
EIF4A2
AATTCCGGTCAGGGTCAAGTC
GCCACACCTTTCCTCCCAAA
166
58
TOP1
GGCGAGTGAATCTAAGGATAATGAA TGGATATCTTAAAGGGTACAGTGAA
97
58
PGK1
GCTGGACAAGCTGGATGTTA
GGCTCCATTGTCCAAGCAGA
142
58
GAPDH
GGAAGCCCCATCACCATCTT
CGCCCCACTTGATTTTGG
54
58
ACTG1
AGCGCAAGTACTCAGTGTGG
CTACGCATCTGCTCAGTCCA
149
58
RPL13
AGCCTACGAGAAAGTTTGCCTAT
TCTTCTTCCTGTAGTGGATCTTGGC
126
58
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Table 3 Forward and reverse primers used in the microfluidic RT- qPCR at 58°C annealing temperature. The
sequences for GAPDH, ACTG1, and RPL13 are the same as those for table 1.

Gene name
APP
CAPN1
CAPNS1
MAPK14
MAPT
MARK1
PRKAR1A
PRKAR2A
PRKAR2B
CSNK2A1
CSNK2A2
PRKCE
AKT3
MAPK1
NCSTN
GAPDH
ACTG1
RPL13

Forward primer (5' to 3')
GACCACTCGACCAGGTTCTG
TTTGACCTGGACAAGTCGGG
GGGTTCCACCTGAATGAGCA
TTGTTTCCTGGCACAGACCAT
CGTCAAGTCCAAGATCGGCT
CTGGCAGTACAACCCAGAGAG
GTGCTACAACGTCGGTCAGA
TGTGCCCCTCCTTAAATCGC
TCATTGCTCAGGGAGATTCGG
CGTCAGCAGCGCCAATATGA
CAGCCCTGAGGCCCTAGAT
TCAAACCGCGCATTAAAACCA
GAGGGGAGTCATCATGAGCG
CGTGACCTCAAGCCTTCCAA
CTTGTCTCCTGCCTTCGAACT
GGAAGCCCCATCACCATCTT
AGCGCAAGTACTCAGTGTGG
AGCCTACGAGAAAGTTTGCCTAT

Amplicon Annealing
Reverse primer (5' to 3')
Size
Temp (°C)
GCCCACCATGAGACCAATGA
175
58
AACATGGTCTCTAGCCGCAC
179
58
CCTGGATTTGTCCAGTGCCA
163
58
TTCGGCATCTGCGTCAAAGA
137
58
CTCCCGGGACGTGTTTGATA
143
58
CCCGTTTCATGGGATGGTGA
187
58
CTTAACGCACTTCAAGGGGC
144
58
CTGGTTCCCACCATCCTTGT
196
58
CTCCAAAGTACTGTCCCCGC
147
58
TTGGCAGCAGCAATCACTGG
96
58
AAAGCACAGCATTGTCTGCAC
146
58
ATTGCTTCGTCCACAAGGGT
59
58
TGAGCCATCTGTCTTCAAAAGGA
115
58
CCCTGTACCAACGTGTAGCC
139
58
GGATGCCGAAGCCCACTATC
149
58
CGCCCCACTTGATTTTGG
54
58
CTACGCATCTGCTCAGTCCA
149
58
TCTTCTTCCTGTAGTGGATCTTGGC
126
58

Results
QuantStudio qPCR to select Housekeeping Gene(s) for the amygdala
From the QuantStudio results for each housekeeping gene, the average Ct values were
graphed against the log of the RNA concentration of the standard curve to calculate the slope (a
measure of the amplification efficiency). See figure 2 for the results of these graphs. The slopes
for these genes: ACTG1, EIF4A2, PGK1, TOP1, CYC1, GAPDH, RPL13, UBE2D2 were -3.31, 3.34, -3.97, -3.44, -3.32, -3.21, -3.45, -3.48, respectively. Thus, all of the primer pairs tested
showed good efficiency.
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Standard deviation was also calculated for all Ct averages and ranged between 0.01 – 0.5
per Ct average. The genes closest to a slope of -3.2 were automatically selected as housekeeping
genes to use in further RT-qPCR tests (GAPDH and ACTG1). The third gene primer selected to
use in further RT-qPCR tests was the gene with the closest slope to -3.2 and smallest amount of
standard deviations within each point of its 8-point standard curve (RPL13). The three
housekeeping genes identified (GAPDH, ACTG1 and RPL13) were then used as references genes
in the microfluidic qPCR to validate the DEGs using samples from experiment 1 and experiment
2.

Figure 2 Efficiency graphs for the housekeeping genes tested using QuantStudio RT-qPCR with line of best fit
equations and R2 values.

Experiment 1 and 2 Data Processing
We compared the expression levels between groups of the different housekeeping genes
and selected the one(s) that showed no differences between treatment. For instance, RPL13 was
used after it was confirmed the different experimental treatments did not alter its expression in
the AMG between groups (independent t-test, p=0.79 for experiment 1 and p=0.60 for
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experiment 2). ACTG1 and GAPDH were found to be differentially expressed (p=8.65E-03 and
p=1.59E-03, respectively). Using independent t-tests, differences in the mean expression
between experimental groups respective to each experiment (1 or 2) were analyzed (IBM SPSS
Statistics; Armonk, NY, USA). Levene’s test for homogeneity of variances was used before
using the independent t-test. When the sample variance was heterogeneous (p > 0.05), the
Welch–Satterthwaite method was used to interpret the results of the SPSS t-test output.
Experiment 1 Amyloid Processing Pathway
During the analysis of the subjects from experiment 1, one subject was found to be an
extreme outlier for all genes, determined by SPSS software. SPSS considers an extreme outlier if
the data falls outside of the ranges: 3rd quartile + 3*interquartile range and 1st quartile –
3*interquartile range. Based on this, the outlier was excluded from t-tests for all genes tested.
Another sample was found to be an outlier for CSNK2A1 and PRKAR2B, determined in SPSS by
falling outside the ranges: 3rd quartile + 1.5*interquartile range and 1st quartile –
1.5*interquartile range. The same sample was found to be an extreme outlier for APP and MAPT
(parameters identified previously). Because this sample was not consistent as an extreme outlier
across all genes, it was left in for the t-test analysis.
From the previously identified genes in the amyloid processing pathway for the AMG, 15
genes were found to be differentially expressed (p < 0.05) (figure 3a) using RT-qPCR analysis
between the OvH and OvH-HT females (samples from experiment 1). This was consistent with
the data from the RNAseq findings (figure 3b). All of DEGs selected to test were significantly
downregulated in the HT using RT-qPCR (table 4a), which was in agreement with the RNAseq
findings (table 4b).
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Figure 3 (a) Normalized expression boxplots from RT-qPCR data for experiment 1 with OvH vs OvH-HT rhesus
macaque females. (b) Normalized counts boxplots from RNAseq data for experiment 1 with OvH vs OvH-HT
rhesus macaque females, taken from Cervera-Juanes et al. paper [34].
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Table 4 (a) Levene’s Test for Homogeneity of Variances p-values and associated equal variance t-test or Welch–
Satterthwaite t-test p-values from experiment 1 RT-qPCR results from tested amyloid processing pathway genes. (b)
Amyloid processing pathway genes selected for validation testing from Cervera-Juanes et al. paper [34] RNAseq
data and their respective p-values.

Experiment 2 Amyloid Processing Pathway
Using the genes identified as DEGs for experiment 1, the same primers were tested on the
samples from experiment 2 between old and young females to determine if any of these effects
could be seen with age under a regular diet. SPSS identified one outlier for APP outside the
ranges of: 3rd quartile + 1.5*interquartile range and 1st quartile – 1.5*interquartile range and two
significant outliers for MAPK14. These outliers were not excluded because they were not
consistent in across other genes, suggesting they are accurate values for experiment 2. Of the
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genes involved in the amyloid processing pathway that were selected for testing with RT-qPCR,
none of them were found to be significant (p < 0.05) for experiment 2 (figure 4a & b).
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Figure 4 (a) Normalized expression boxplots from RT-qPCR data for experiment 2 with young vs old rhesus
macaque females. (b) Table with Levene’s Test for Homogeneity of Variances p-values and associated equal
variance t-test or Welch–Satterthwaite t-test p-values from experiment 2 RT-qPCR results from tested amyloid
processing pathway genes.
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Discussion
The purpose of this study was to confirm the results from the Cevera-Juanes et al. paper
and validate the RNAseq findings from that study using the same AMG RNA samples. We were
able to validate the RNAseq data because of the 15 genes selected for validation using RT-qPCR,
all of them were verified to be significantly different. More specifically, the selected genes were
also downregulated in the HT group, same as the RNAseq data [34].
Of the genes selected for validation testing, the RNAseq data had counts per million as
low as 2.3 mean logCPM per experimental group for experiment 1 [34]. However, using this low
cutoff value does not guarantee that all genes at that level will be differentially expressed. With
the qPCR findings confirming the genes at 2.3 logCPM were differentially expressed, it allows
us to say with confidence that using a cutoff of 2.3 logCPM in the future is valid for this type of
dataset, and the genes at this level will be differentially expressed.
The amyloid processing pathway is responsible for the proteolytic cleavage of the
amyloid precursor protein (APP) to Aβ peptide, which has been associated with AD [51-52]. The
genes APP (amyloid precursor protein), NCSTN (nicastrin), and MAPT (microtubule associated
protein tau) are all involved in the generation of Aβ. During amyloid processing, APP is cleaved
by the γ-secretase complex, which contains the protein encoded by NCSTN [53]. Coincidentally,
the findings of this study showed that these genes, along with the rest of selected genes for
validation are downregulated with HT in females under a chronic WSD.
Additional genes that have been implicated in the AD pathology, MARK, AKT, MARK,
and MAPT [34,54] through their contributions to developing neuritic plaques and neurofibrillary
tangles were also investigated in this study. Many neurodegenerative diseases are characterized
by the abnormal clustering of tau in neurons or glia, including AD, and MAPT is a principal
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component of these tau tangles [54]. With Aβ plaques and neurofibrillary tangles being
indicators of AD development [42, 54], our results could indicate that chronic WSD may
increase risk for AD, and that HT in these individuals could have a down-regulative effect on the
pathway that synthesizes Aβ and tau, indicating positive cognitive benefits of HT use on
menopausal women on WSD. This correlates with other studies which have found
neuroprotective effects of estrogen HTs on women in early menopause such as protecting
neurons against beta-amyloid toxicity and calcium toxicity [55-56]. Our results in rhesus
macaques contribute to this evidence and the use of HT at menopause onset, while exercising
caution that long-term WSD could be causing increased risk of AD and decreasing the
effectiveness of HT treatments.
Although there are important differences in experimental design between the subjects
included in experiment 1 and experiment 2, we included experiment 2 in this validation study to
determine if alterations in the amyloid pathway naturally occur with age, independently of diet
and estrogen levels. With no significant differences in gene expression observed in genes within
the amyloid processing pathway for experiment 2 subjects, we can conclude there are no
significant expression changes in the amygdala between young rhesus macaque pre-menopausal
females and post-menopausal females on a SD. But, as previously established, WSD is a
common factor contributing to obesity worldwide [28], so the genetic link between increased
neurodegeneration and menopause suggested could have more to do with WSD and obesity than
age [5,9]. This is supported by other studies which indicate a strong connection between obesity
and impaired cognitive function, including increased risk of neurodegenerative diseases like AD
[57-59].
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We can infer from these two experiments that the WSD during lack of estrogens is a
strong risk factor for neurodegenerative risk in females. The downregulation of the amyloid
processing genes indicates that there may be an insulating or neuroprotective effect from HT
treatment, though without further research, it is unclear if WSD is exacerbating the condition in
the absence of HT. We are currently conducting a similar study, analyzing the effects of HT in
OvH females under a regular diet. This study will further clarify the risk of WSD for AD.
Future directions for this research would be to continue research on HT and WSD
correlations for the amyloid processing pathway genes. We are planning to use
immunohistochemistry (IHC) and Western blots to further visualize the changes in the amyloid
processing pathway of the AMG. Through IHC and Western blots of this tissue, we will be able
to see if the changes in gene expression correlate to proteomic changes. These findings along
with future studies which also account for diet type and OvH vs non-OvH, would then allow
relative expression values to be compared across experiments and result in more definitive
findings about what is causing downregulation of the amyloid processing pathway.
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